Organic　chromium　is　of　great　interest　and　has　become　an　important　chromium　supplement　resource　in　recent　years　because　of　its　low　toxicity　and　easy　absorption.　In　our　previous　study,　we　synthesized　a　novel　organic　chromium　[GLP-Cr]　through　the　chelation　of　Ganoderma　lucidum　polysaccharide　and　chromium　(III).　The　purpose　of　this　study　was　to　investigate　the　beneficial　effects　of　GLP-Cr　on　the　improvement　of　metabolic　syndromes　(MetS)　in　mice　fed　with　a　high-fat　and　high-fructose　diet　(HFHFD)　and　its　mechanism　of　action.　The　results　indicated　that　oral　administration　of　GLP-Cr　inhibited　the　excessive　exaltation　of　body　weight,　glucose　tolerance,　fasting　blood　glucose　and　lipid　levels,　hepatic　total　cholesterol　(TC),　triglyceride　(TG)　levels　caused　by　HFHFD.　Besides,　16S　rRNA　amplicon　sequencing　showed　that　GLP-Cr　intervention　evidently　ameliorated　intestinal　microbiota　dysbiosis　by　changing　the　proportions　of　some　intestinal　microbial　phylotypes.　In　addition,　correlation　network-based　analysis　indicated　that　the　key　intestinal　microbial　phylotypes　were　closely　related　to　biochemical　parameters　associated　with　MetS　under　GLP-Cr　intervention.　Liver　metabolomics　analysis　suggested　that　GLP-Cr　intervention　significantly　regulated　the　levels　of　some　biomarkers　involved　in　alpha-linolenic　acid　metabolism,　fatty　acid　biosynthesis,　steroid　hormone　biosynthesis,　glycerophospholipid　metabolism,　glycerolipid　metabolism,　steroid　hormone　biosynthesis,　primary　bile　acid　biosynthesis,　and　so　on.　Moreover,　GLP-Cr　intervention　regulated　liver　mRNA　levels　of　key　genes　associated　with　glucose　and　lipid　metabolism.　The　mRNA　level　of　glucose　transporter　type　4　(Glut4)　was　markedly　increased　by　GLP-Cr　intervention,　and　the　mRNA　levels　of　phosphoenolpyruvate　carboxykinase　(Pepck)　and　glucose-6-phosphatase　(G6Pase)　in　the　liver　were　significantly　decreased.　Meanwhile,　GLP-Cr　intervention　significantly　decreased　hepatic　mRNA　levels　of　cluster　of　differentiation　36　(Cd36),　acetyl-CoA　carboxylase　1　(Acc1)　and　sterol　regulatory　element　binding　protein-1c　(Srebp-1c),　indicating　that　GLP-Cr　intervention　inhibited　the　excessive　accumulation　of　free　fatty　acids　in　the　liver.　These　findings　suggest　that　the　prevention　of　hyperglycemia　and　dyslipidemia　by　GLP-Cr　may　be　closely　related　to　the　regulation　of　gut　microbial　composition　and　hepatic　metabolic　pathways,　thus　GLP-Cr　can　be　serving　as　a　functional　component　in　the　prevention　of　MetS.